Trend — Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a (M0224) in Medicare, the United States
Trend · M0224 · National · CY2024
Twelve-year services series · M0224 · the United Statesincluded in Explore
The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.
Compound growth · endpointsincluded in Explore
The compound annual growth for M0224 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.